Exploratory Clinical Trial of (4 <i>S</i> )-4-(3-[18F]fluoropropyl)- <scp>l</scp> -glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Abstract

[(18)F]FSPG seems to be a promising tracer with a relatively high cancer detection rate in patients with NSCLC. [(18)F]FSPG PET may assess x(C)(-) transporter activity in patients with cancer.